Jacob Lalezari

13.8k total citations · 2 hit papers
138 papers, 6.9k citations indexed

About

Jacob Lalezari is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Jacob Lalezari has authored 138 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Infectious Diseases, 65 papers in Epidemiology and 52 papers in Virology. Recurrent topics in Jacob Lalezari's work include HIV/AIDS drug development and treatment (63 papers), HIV Research and Treatment (52 papers) and Hepatitis C virus research (49 papers). Jacob Lalezari is often cited by papers focused on HIV/AIDS drug development and treatment (63 papers), HIV Research and Treatment (52 papers) and Hepatitis C virus research (49 papers). Jacob Lalezari collaborates with scholars based in United States, United Kingdom and Germany. Jacob Lalezari's co-authors include William Drew, Calvin Cohen, Edwin DeJesus, Joseph J. Eron, Stephen Follansbee, Howard S. Jaffe, Ralph DeMasi, Peter J. Piliero, Miklos Salgo and John Delehanty and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jacob Lalezari

134 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Jacob Lalezari, Calvin Cohen et al. New England Journal of Medicine profile →
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Jacob Lalezari

Since Specialization

Citations

This map shows the geographic impact of Jacob Lalezari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob Lalezari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob Lalezari more than expected).

Fields of papers citing papers by Jacob Lalezari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob Lalezari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob Lalezari. The network helps show where Jacob Lalezari may publish in the future.

Co-authorship network of co-authors of Jacob Lalezari

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob Lalezari. A scholar is included among the top collaborators of Jacob Lalezari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob Lalezari. Jacob Lalezari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial 2025 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joseph Gathe, (unknown), Moti Ramgopal, Charlotte-Paige Rolle, Otto O. Yang, William E. Sanchez, Jacob Lalezari, Alok Krishen, Jonah B. Sacha, Scott G. Hansen, (unknown)	1
2	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection 2019 ·Gastroenterology ·Man‐Fung Yuen, Edward Gane, Dong Joon Kim, Frank Weilert, Henry Lik‐Yuen Chan, Jacob Lalezari, Seong Gyu Hwang, Tuan Nguyen, Osvaldo Flores, George D. Hartman, (unknown), Oliver Lenz, Thomas N. Kakuda, Willem Talloen, Christian Schwabe, Klaus Klumpp, Nathaniel Brown	117
3	High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis 2016 ·Gastroenterology ·Edward Gane, Fred Poordad, Stanley Wang, Armen Asatryan, Paul Y. Kwo, Jacob Lalezari, David Wyles, Tarek Hassanein, Humberto Aguilar, Benedict Maliakkal, Ran Liu, Chih-Wei Lin, Teresa I. Ng, Jens Kort, Federico Mensa	72
4	Primary Efficacy Endpoint and Safety Results of Ibalizumab (IBA) in a Phase 3 Study of Heavily Treatment-Experienced Patients with Multi-Drug Resistant (MDR) HIV-1 Infection 2016 ·Jacob Lalezari	0
5	1221 NO S282T MUTATION DETECTED BY DEEP SEQUENCING IN A LARGE NUMBER OF HCV PATIENTS WHO RECEIVED GS-7977 WITH RBV AND/OR GS-0938: THE QUANTUM STUDY 2013 ·Journal of Hepatology ·Evguenia Svarovskaia, Hadas Dvory‐Sobol, Viktoria Gontcharova, (unknown), (unknown), William T. Symonds, Jacob Lalezari, Michael D. Miller, Hongmei Mo	4
6	Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial 2013 ·Hepatology ·Mark Sulkowski, Tarik Asselah, Jacob Lalezari, Péter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Schérer, Gerhard Nehmiz, Gerhard Steinmann, Wulf O. Böcher	86
7	2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS 2010 ·Journal of Hepatology ·Ira M. Jacobson, Paul J. Pockros, Jacob Lalezari, E. Läwitz, M. Rodríguez‐Torres, E DeJesus, Felix Haas, Claudia Martorell, (unknown), Vivek S. Purohit, Subasree Srinivasan, (unknown), Khurram Rana, Jennifer Hammond	18
8	Hepatic safety and tolerability in the maraviroc clinical development program 2010 ·AIDS ·Ayman Ayoub, (unknown), James Goodrich, Jayvant Heera, Andy I. M. Hoepelman, Jacob Lalezari, (unknown), Mark Nelson, Elna van der Ryst, Howard Mayer	12
9	Restoration of Blood Total Glutathione Status and Lymphocyte Function Following α -Lipoic Acid Supplementation in Patients with HIV Infection 2008 ·The Journal of Alternative and Complementary Medicine ·R J Jariwalla, Jacob Lalezari, (unknown), Sam E. Mansour, (unknown), (unknown), (unknown)	35
10	O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults 2008 ·Journal of the International AIDS Society ·Jacob Lalezari, E DeJesus, Olayemi Osiyemi, Peter Ruane, (unknown), Robert J. Ryan, (unknown), Thomas N. Kakuda, James Witek	6
11	Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy 2008 ·Journal of Interferon & Cytokine Research ·Richard T. Davey, Peter Pertel, Alice Benson, Delanie J. Cassell, Brian Gazzard, Mark Holodniy, Jacob Lalezari, Yves Lévy, Ronald T. Mitsuyasu, Frank J. Palella, Richard B. Pollard, Prabhu Rajagopalan, Michael S. Saag, Robert A. Salata, Beverly E. Sha, Shurjeel Choudhri	5
12	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection breakdown → 2008 ·New England Journal of Medicine ·Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, (unknown), (unknown), John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer	570
13	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2003 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	6
14	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2002 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	152
15	Randomized, Controlled Study of the Safety and Efficacy of Intravenous Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS 1998 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Jacob Lalezari, Gary N. Holland, Françoise Kramer, George McKinley, Carol A. Kemper, (unknown), Robert G. Nelson, W. D. Hardy, Baruch D. Kuppermann, Donald W. Northfelt, M Youle, Margaret Johnson, Richard A. Lewis, David V. Weinberg, Gary L. Simon, Richard A. Wolitz, (unknown), Robert Stagg, Howard S. Jaffe	72
16	Mutation in region III of the DNA polymerase gene associated with dual ganciclovir-foscarnet resistance in cytomegalovirus (CMV) isolates from three subjects receiving prolonged antiviral therapy 1997 ·Clinical Infectious Diseases ·Sunwen Chou, Gail I. Marousek, (unknown), Jacob Lalezari, (unknown), (unknown)	1
17	Cidofovir 1997 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Jacob Lalezari	23
18	Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease 1997 ·The Journal of Infectious Diseases ·Sunwen Chou, Gail I. Marousek, (unknown), Stephen Follansbee, (unknown), Jacob Lalezari, Richard C. Miner, W. Lawrence Drew	135
19	Pharmacokinetic, Safety, and Antiviral Profiles of Oral Ganciclovir in Persons Infected with Human Immunodeficiency Virus: A Phase I/II Study 1995 ·The Journal of Infectious Diseases ·Stephen A. Spector, David F. Busch, Stephen Follansbee, Kathleen Squires, Jacob Lalezari, Mark Z. Jacobson, James D. Connor, Donald Jung, Anna Shadman, (unknown), William Buhles, W. Lawrence Drew, (unknown)	85
20	Treatment With Intravenous (S)-1-[3-Hydroxy-2-(Phosphonylmethoxy)Propyl]-Cytosine Of Acyclovir-Resistant Mucocutaneous Infection With Herpes Simplexvirus In A Patient With Aids 1994 ·The Journal of Infectious Diseases ·Jacob Lalezari, William Drew, (unknown), David J. Miner, Sharon Safrin, William F. Owen, (unknown), Pearl Fisher, Howard S. Jaffe	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact